Agile Therapeutics (NASDAQ:AGRX) Stock Passes Below 200 Day Moving Average of $1.44

Agile Therapeutics, Inc. (NASDAQ:AGRX) shares crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $1.44 and traded as low as $0.37. Agile Therapeutics shares last traded at $0.38, with a volume of 47,561 shares.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on AGRX shares. StockNews.com started coverage on shares of Agile Therapeutics in a research report on Saturday. They set a “sell” rating for the company. Maxim Group reaffirmed a “hold” rating on shares of Agile Therapeutics in a research report on Monday, March 18th.

Agile Therapeutics Price Performance

The firm has a market cap of $2.61 million, a P/E ratio of -0.04 and a beta of 1.42. The company’s 50-day moving average is $0.64 and its two-hundred day moving average is $1.44.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. bought a new position in shares of Agile Therapeutics in the fourth quarter worth about $40,000. Armistice Capital LLC lifted its holdings in shares of Agile Therapeutics by 10.2% in the fourth quarter. Armistice Capital LLC now owns 108,000 shares of the specialty pharmaceutical company’s stock worth $211,000 after acquiring an additional 10,000 shares during the last quarter. State Street Corp bought a new position in shares of Agile Therapeutics in the second quarter worth about $32,000. Virtu Financial LLC bought a new position in shares of Agile Therapeutics in the fourth quarter worth about $32,000. Finally, BlackRock Inc. lifted its holdings in shares of Agile Therapeutics by 538.6% in the third quarter. BlackRock Inc. now owns 303,799 shares of the specialty pharmaceutical company’s stock worth $91,000 after acquiring an additional 256,227 shares during the last quarter. Institutional investors own 10.92% of the company’s stock.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc, a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.